128 related articles for article (PubMed ID: 38376316)
21. A Case of Metastatic Submandibular Salivary Duct Carcinoma that Completely Responded to Pembrolizumab Monotherapy.
Nakaishi M; Sakamoto K; Sakanushi A; Matsunobu T; Terasaki M; Okubo K
J Nippon Med Sch; 2023 Sep; 90(4):356-362. PubMed ID: 36273905
[TBL] [Abstract][Full Text] [Related]
22. Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma.
Taha T; Billan S
Anticancer Drugs; 2022 Jan; 33(1):e760-e763. PubMed ID: 34387606
[TBL] [Abstract][Full Text] [Related]
23. Primary and Secondary/ Metastatic Salivary Duct Carcinoma Presenting within the Sinonasal Tract.
Agaimy A; Mueller SK; Bishop JA; Chiosea SI
Head Neck Pathol; 2021 Sep; 15(3):769-779. PubMed ID: 33428064
[TBL] [Abstract][Full Text] [Related]
24. Metastatic salivary duct carcinoma in cardiac and pleural effusions: A case report with immunocytochemical analysis for androgen receptor and HER2.
Ito H; Ishida M; Sando K; Okano K; Ebisu Y; Fujisawa T; Iwai H; Tsuta K
Mol Clin Oncol; 2019 Jan; 10(1):78-82. PubMed ID: 30655980
[TBL] [Abstract][Full Text] [Related]
25. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Falchook GS; Lippman SM; Bastida CC; Kurzrock R
Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
[TBL] [Abstract][Full Text] [Related]
26. Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland.
Yamamoto H; Uryu H; Segawa Y; Tsuneyoshi M
Pathol Int; 2008 May; 58(5):322-6. PubMed ID: 18429833
[TBL] [Abstract][Full Text] [Related]
27. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma.
Kapadia SB; Barnes L
Mod Pathol; 1998 Nov; 11(11):1033-8. PubMed ID: 9831198
[TBL] [Abstract][Full Text] [Related]
28. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature.
Fan CY; Wang J; Barnes EL
Am J Surg Pathol; 2000 Apr; 24(4):579-86. PubMed ID: 10757407
[TBL] [Abstract][Full Text] [Related]
29. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.
Mitani Y; Rao PH; Maity SN; Lee YC; Ferrarotto R; Post JC; Licitra L; Lippman SM; Kies MS; Weber RS; Caulin C; Lin SH; El-Naggar AK
Clin Cancer Res; 2014 Dec; 20(24):6570-81. PubMed ID: 25316813
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report.
Yang ZY; Huang JH; Chen B; Xu CW; Lei L; Wang XJ; Fang MY
Front Oncol; 2020; 10():559057. PubMed ID: 33123470
[No Abstract] [Full Text] [Related]
31. Blockade of Androgen-induced Malignant Phenotypes by Flutamide Administration in Human Salivary Duct Carcinoma Cells.
Kamata YU; Sumida T; Murase R; Nakano H; Yamada T; Mori Y
Anticancer Res; 2016 Nov; 36(11):6071-6075. PubMed ID: 27793934
[TBL] [Abstract][Full Text] [Related]
32. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance.
Nagao T; Gaffey TA; Visscher DW; Kay PA; Minato H; Serizawa H; Lewis JE
Am J Surg Pathol; 2004 Mar; 28(3):319-26. PubMed ID: 15104294
[TBL] [Abstract][Full Text] [Related]
33. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.
Luk PP; Weston JD; Yu B; Selinger CI; Ekmejian R; Eviston TJ; Lum T; Gao K; Boyer M; O'Toole SA; Clark JR; Gupta R
Head Neck; 2016 Apr; 38 Suppl 1():E1838-47. PubMed ID: 26699379
[TBL] [Abstract][Full Text] [Related]
34. Salivary Duct Carcinoma of the Parotid Gland Originating from an Epithelial-Myoepithelial Carcinoma: Report of a Rare Case.
Hamamoto Y; Harada H; Suzuki M; Fujii T; Nakatsuka SI
Head Neck Pathol; 2020 Mar; 14(1):283-289. PubMed ID: 30937832
[TBL] [Abstract][Full Text] [Related]
35. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
[TBL] [Abstract][Full Text] [Related]
36. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
Udager AM; Chiosea SI
Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
[TBL] [Abstract][Full Text] [Related]
37. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma.
Liang L; Williams MD; Bell D
Head Neck Pathol; 2019 Dec; 13(4):529-534. PubMed ID: 30390196
[TBL] [Abstract][Full Text] [Related]
38. The implications of TrkA and MET aberrations in de novo salivary duct carcinoma.
Ryu HJ; Koh YW; Yoon SO
Hum Pathol; 2018 Nov; 81():18-25. PubMed ID: 29753009
[TBL] [Abstract][Full Text] [Related]
39. Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute.
Beck ACC; Lohuis PJFM; Al-Mamgani A; Smit LA; Klop WMC
Eur Arch Otorhinolaryngol; 2018 Jul; 275(7):1885-1892. PubMed ID: 29785551
[TBL] [Abstract][Full Text] [Related]
40. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Herpen CML
Oral Oncol; 2022 Feb; 125():105703. PubMed ID: 34995931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
